This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: FDA Updates for LLY, AZN, MRK, BMY and SNY
by Kinjel Shah
FDA approves Lilly's (LLY) selpercatinib for RET-altered lung and thyroid cancers and AstraZeneca (AZN)/Merck's (MRK) Lynparza for new ovarian cancer use.
Roche Posts Positive Phase II Results on Immunotherapy Combo
by Zacks Equity Research
Roche's (RHHBY) mid-stage study on immunotherapy, tiragolumab, combined with PD-L1 checkpoint inhibitor, Tecentriq, meets co-primary endpoints.
Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - May 14, 2020
by Zacks Equity Research
Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - May 14, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Bristol-Myers Gets Refusal to File Letter for CAR-T Therapy BLA
by Zacks Equity Research
Bristol-Myers' (BMY) BLA seeking approval for CAR-T therapy candidate, idecabtagene vicleucel, for treating relapsed and refractory multiple myeloma gets FDA's refusal. The company plans to re-submit the BLA by July.
Biotech ETFs to Gain From Latest Advancements in Cancer Drugs
by Sweta Jaiswal, FRM
The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.
Drug Sector Highly Resilient Amid Coronavirus Mayhem: 5 Picks
by Kinjel Shah
Here we highlight five large drugmakers that can be added to one's portfolio amid the coronavirus crisis.
AstraZeneca's Lynparza Gets FDA Nod for New Ovarian Cancer Use
by Zacks Equity Research
FDA approves AstraZeneca's (AZN) PARP inhibitor Lynparza as a first-line maintenance treatment for HRD-positive advanced ovarian cancer. The approval was based on data from the phase III PAOLA-1 study.
Biotech Stock Q1 Earnings Due on May 12: ADPT, VIR, TPTX
by Kinjel Shah
Let us take a look at three biotech companies due to release their first-quarter financial results on May 12.
Nektar's (NKTR) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Nektar (NKTR) reports encouraging first-quarter 2020 results. The company continues to progress with its pipeline candidates.
Moderna (MRNA) Q1 Loss Narrows, Revenues Miss Estimates
by Zacks Equity Research
Moderna (MRNA) reports narrower-than-expected first-quarter loss. The company plans to initiate phase II study on coronavirus vaccine soon.
Esperion (ESPR) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports encouraging first-quarter results. The company records product revenues for the first time during the quarter.
Immunomedics (IMMU) Q1 Earnings Beat, Trodelvy in Focus
by Zacks Equity Research
Immunomedics (IMMU) reports a narrower-than-expected Q1 loss. The focus is on its recently approved drug, Trodelvy, for mTNBC.
Bristol-Myers' (BMY) Q1 Earnings & Sales Beat Estimates
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the first quarter on strong performance of Revlimid and Eliquis.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - May 07, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
The Zacks Analyst Blog Highlights: Merck, PayPal, Royal Dutch Shell, BlackRock and General Electric
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, PayPal, Royal Dutch Shell, BlackRock and General Electric
Exelixis (EXEL) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the first quarter and maintains annual outlook amid coronavirus.
Top Research Reports for Merck, PayPal & Royal Dutch Shell
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), PayPal (PYPL) and Royal Dutch Shell (RDS.A).
Corcept (CORT) Q1 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.
Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More
by Kinjel Shah
Let us take a look at five drug/biotech companies due to release their first-quarter financial results on May 6.
5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
Epizyme's (EPZM) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Epizyme (EPZM) reports a narrower-than-expected Q1 loss but misses on revenues.
Seattle Genetics (SGEN) Q1 Earnings Beat, Adcetris Aids Sales
by Zacks Equity Research
Seattle Genetics (SGEN) reports narrower-than-expected loss in Q1 while its revenues too beat estimates.
Moderna (MRNA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Progress of its pipeline candidates, especially coronavirus vaccine, is likely to have increased Moderna's (MRNA) operating expenses in the first quarter.
Factors Setting the Tone for Bristol-Myers (BMY) Q1 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports first-quarter 2020 results.